New clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analyses (Q30419928)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22852587 AND SRC:MED&resulttype=core&format=json

9 February 2020

review article

0 references

title

New clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analyses (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22852587 AND SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

23 July 2019

chronic obstructive pulmonary disease

1 reference

23 July 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22852587 AND SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Douglas W Mapel

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22852587 AND SRC:MED&resulttype=core&format=json

9 February 2020

publication date

1 October 2012

2 references

23 July 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22852587 AND SRC:MED&resulttype=core&format=json

9 February 2020

2 references

23 July 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22852587 AND SRC:MED&resulttype=core&format=json

9 February 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22852587 AND SRC:MED&resulttype=core&format=json

9 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22852587 AND SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

869-885

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22852587 AND SRC:MED&resulttype=core&format=json

Cause-specific mortality adjudication in the UPLIFT® COPD trial: Findings and recommendations

9 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Safety of indacaterol in the treatment of patients with COPD

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Current controversies and future perspectives in chronic obstructive pulmonary disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Tiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Predictors of mortality in COPD.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

The role of combination inhaled corticosteroid/long-acting beta-agonist therapy in COPD management.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Physical activity, health status and risk of hospitalization in patients with severe chronic obstructive pulmonary disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Increased risk of myocardial infarction and stroke following exacerbation of COPD.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Multivariate models of determinants of health-related quality of life in severe chronic obstructive pulmonary disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Definitions of exacerbations: does it really matter in clinical trials on COPD?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Cardiovascular safety of tiotropium in patients with COPD.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Design and analysis issues for economic analysis alongside clinical trials

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Effects of mode and order of administration on generic health-related quality of life scores

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Present and future costs of COPD in Iceland and Norway: results from the BOLD study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Obstructive lung disease models: what is valid?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Cost-effectiveness of combination therapy for chronic obstructive pulmonary disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Occupational exposures and COPD: an ecological analysis of international data.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Smoking-attributable mortality, years of potential life lost, and productivity losses--United States, 2000-2004

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Pharmacoeconomics in COPD: lessons for the future

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

A Markov model to evaluate hospital readmission

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Exacerbations in chronic obstructive pulmonary disease: do they contribute to disease progression?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and bronchodilators for severe and very severe COPD patients.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

US norms for six generic health-related quality-of-life indexes from the National Health Measurement study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Assessment of the economic burden of COPD in the U.S.: a review and synthesis of the literature

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Economic modeling in chronic obstructive pulmonary disease.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Health economics of chronic obstructive pulmonary disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Predictors of mortality in patients with emphysema and severe airflow obstruction

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Chronic obstructive pulmonary disease: from unjustified nihilism to evidence-based optimism

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Predicting the costs of managing patients with chronic obstructive pulmonary disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

A dynamic population model of disease progression in COPD.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

US valuation of the EQ-5D health states: development and testing of the D1 valuation model.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

COPD exacerbations: definitions and classifications.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

The burden of illness and economic evaluation for COPD.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

A comparative review of four preference-weighted measures of health-related quality of life

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

An economic overview of chronic obstructive pulmonary disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Toward a consensus definition for COPD exacerbations

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Suboptimal medical therapy in COPD: exploring the causes and consequences

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Decline of FEV1 by age and smoking status: facts, figures, and fallacies

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Economic appraisal of asthma and COPD care: a literature review 1980-1991

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

The natural history of chronic airflow obstruction

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

The occupational burden of chronic obstructive pulmonary disease

20 June 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

The influence of chronic respiratory conditions on health status and work disability

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Economic analysis of the Confronting COPD survey: an overview of results

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

A New Method for Examining the Cost Savings of Reducing COPD Exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

The burden of COPD in the U.S.A.: results from the Confronting COPD survey

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

The burden of COPD in Canada: results from the Confronting COPD survey

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

The burden of COPD in the U.K.: results from the Confronting COPD survey

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

The burden of COPD in Spain: results from the Confronting COPD survey

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

The burden of COPD in The Netherlands: results from the Confronting COPD survey

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

The burden of COPD in Italy: results from the Confronting COPD survey

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

The burden of COPD in France: results from the Confronting COPD survey

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Costs of COPD in Sweden according to disease severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

The cost effectiveness of early treatment with fluticasone propionate 250 microg twice a day in subjects with obstructive airway disease. Results of the DIMCA program.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Costs of COPD exacerbations in the emergency department and inpatient setting

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish healthcare perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Characteristics of patients admitted for the first time for COPD exacerbation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

The minimally clinically important difference in generic utility-based measures

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Measurement of health-related quality of life in the national emphysema treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Impairment of quality of life in women with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Socioeconomic status and health-related quality of life of patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Validation of the COPD severity score for use in primary care: the NEREA study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Is the EQ-5D responsive to recovery from a moderate COPD exacerbation?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Overdiagnosing subjects with COPD using the 0.7 fixed ratio: correlation with a poor health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

EuroQoL in assessment of the effect of pulmonary rehabilitation COPD patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration Medical System, 1991-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Co-morbidity in mild-to-moderate COPD: comparison to normal and restrictive lung function

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Cardiovascular events in patients with COPD: TORCH study results

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Consideration of Multiple Chronic Diseases in Randomized Controlled Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Economic implications of comorbid conditions among Medicaid beneficiaries with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

The Impact of Ischemic Heart Disease on Symptoms, Health Status, and Exacerbations in Patients With COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Economic burden prior to COPD diagnosis: a matched case-control study in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

A taxonomy of model structures for economic evaluation of health technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Discrete event simulation: the preferred technique for health economic evaluations?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Development and Validation of a Microsimulation Economic Model to Evaluate the Disease Burden Associated with Smoking and the Cost-Effectiveness of Tobacco Control Interventions in Latin America

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Econometric modeling of health care costs and expenditures: a survey of analytical issues and related policy considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11633330-000000000-00000

Deaths from chronic obstructive pulmonary disease--United States, 2000-2005.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

The impact of chronic obstructive pulmonary disease on long-term disability costs

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3625413

Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease

26 November 2018

1 reference

12 December 2020

Validity of a quality of well-being scale as an outcome measure in chronic obstructive pulmonary disease

1 reference

12 December 2020

A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease

1 reference

12 December 2020

A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease

1 reference

12 December 2020

Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?

1 reference

12 December 2020

The direct medical costs of undiagnosed chronic obstructive pulmonary disease

1 reference

12 December 2020

Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity

1 reference

12 December 2020

A threshold regression model for recurrent exacerbations in chronic obstructive pulmonary disease

1 reference

12 December 2020

Costs of chronic obstructive pulmonary disease (COPD) in Italy: the SIRIO study (social impact of respiratory integrated outcomes)

1 reference

12 December 2020

Prevalence and most common causes of disability among adults--United States, 2005

1 reference

12 December 2020

Utilization in COPD: patient characteristics and diagnostic evaluation

1 reference

12 December 2020

Chronic obstructive pulmonary disease surveillance--United States, 1971-2000

1 reference

12 December 2020

10.2165/11633330-000000000-00000

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22852587 AND SRC:MED&resulttype=core&format=json

Dimensions Publication ID

9 February 2020

1044907778

0 references

Fatcat ID

release_m2ueyovnbjhapm63bx576rhgmu

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/m2ueyovnbjhapm63bx576rhgmu

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22852587 AND SRC:MED&resulttype=core&format=json

9 February 2020

PubMed publication ID

22852587

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22852587 AND SRC:MED&resulttype=core&format=json